Independent prognostic role of p16 expression in lung cancer  by Groegera,b, Angela M. et al.
cell cycle machinery, being the final executors in cell
division, potentially could be able to elicit or to con-
tribute to a neoplastic phenotype. These phenomena are
even more relevant in lung cancer, a neoplasm that
affects the respiratory system, which is interacting con-
tinuously with the external environment.
The recent discovery of a new family of cell cycle
regulators called cyclin-dependent kinase inhibitors
(CKIs) has opened up new avenues for study of differ-
T he pathogenesis of lung cancer is characterized byits multiplicity of origins. Different agents (biologi-
cal, chemical, and physical), by acting as initiating or
promoting factors, have been associated with increasing
lung cancer risk. A common molecular basis, however,
underlies all of the different pathogenetic theories. The
external environment manipulates cellular proliferation
and differentiation by stimulating or inhibiting certain
signal transduction pathways. Each component of the
Objectives: The cyclin-dependent kinase p16 (also known as Ink4A, Mts1,
Cdkn2, and Cdkn4i) has been proposed as a tumor suppressor gene
mapped on chromosome segment 9p21. This study evaluated p16 pro-
tein expression in 135 lung cancer specimens and investigated potential
genetic alterations occurring in this gene. Results: We found altered p16
immunohistochemical expression to be a frequent event in lung cancer
and to be independent of either the histologic type or any other clinical-
pathologic feature. Western blot analyses performed on about one third
of the specimens correlated highly with these results. In addition, we
found p16 immunohistochemical expression to be a favorable prognos-
tic factor in lung cancer in that its reduction or loss correlated with a
worse outcome for the patients. Polymerase chain reaction amplification
and direct sequencing of p16 exons 1 and 2 revealed no mutations, indi-
cating that p16-altered expression in lung cancer is not necessarily
linked to mutational events of these genes. Conclusions: We conclude that
p16-altered expression is both an independent and frequent event in
lung cancer and may have an important role in tumorigenesis and in
malignant progression of a significant proportion of these cancers.
However, the actual incidence and relevance of p16 mutations in this
neoplasm continues to be debated, and its analysis seems inconclusive.
Our results suggest a prognostic role for the immunodetection of this
protein on formalin-fixed and paraffin-embedded specimens. They fur-
ther suggest its routine use in the evaluation of the frequently unpre-
dictable behavior of lung cancer. (J Thorac Cardiovasc Surg 1999;
118:529-35)
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ent cell cycle functions. CKIs have the ability to stop
cell cycle progression by interacting directly with sev-
eral cell cycle regulators and also are considered to be
potential tumor suppressor genes. At present, 2 differ-
ent groups of CKIs can be separated on the basis of
sequence homology criteria. The first group includes
p21 (WAF1, Cip1, Cap20, Sdi1, mda6), the first CKI to
be discovered, p27 (Ick, Kip1 and Pic2), and p57 (also
called Kip2). The second group includes p16 (Ink4A,
Mts1, Cdkn2, and Cdkn4i), p15 (Ink4B, Mts2), p18
(Ink4C and Ink6A), and p19/p20 (also called Ink4D
and Ink6B).
The p16 gene encodes a 16-kd protein first identified
in transformed cell lines.1 The detection of significant
levels of p16 in late G1 and S phase only confirms its
role in the inhibition of the cell cycle machine.2 In addi-
tion, p16 is believed to block the activation of cyclin-
dependent kinases 4 and 6 by competing for D cyclin
binding.1 Because p16 is considered to be a specific
regulator of D-type cyclin-dependent kinases and
because the retinoblastoma gene is the best character-
ized substrate of the G1 cyclin-dependent kinases, a
feedback between these 2 cell cycle regulators has been
hypothesized.3,4 This theory is supported by the finding
that increased levels of p16 are always detected in cells
Rb –/–, blocking the interactions between cyclin-
dependent kinases 4 and 6 and the D cyclins.4
However, the transcription factor that should regulate
this mechanism is yet to be identified.
Abnormalities in the above-described p16/Rb path-
way have been reported in different tumors.5-9 It is
widely known that lung cancers of morphologic simi-
larities may behave differently in any assigned stage
group, which may affect markedly the clinical manage-
ment of each patient. We10,11 have reported the involve-
ment of p27 and p21 in lung cancer pathogenesis and
progression. Drawing on our previous findings, we
decided to assess the p16 status in a group of 135
patients who had surgical resection for lung cancer in
an attempt to identify a prognostic marker for this fre-
quent and aggressive neoplasm whose behavior often
seems to be unpredictable.
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Fig 1. Representative p16 immunostainings of lung cancer specimens with the presence of staining of non-neo-
plastic elements (positive internal control). A, Lung cancer with high p16 expression level (· 200). B, Lung can-
cer with medium p16 expression level ( · 200). C, Lung cancer with low p16 expression level ( · 200). D, Lung
cancer negative for p16 expression with a positive internal control (lymphocytes) (· 200).
Material and methods
Tumor specimens. A total of 135 formalin-fixed and
paraffin-embedded lung cancer specimens were included in
the study. All specimens were obtained from patients who
underwent surgical resection (lobectomy or pneumonectomy)
and complete mediastinal lymphadenectomy in the
Department of Cardio-Thoracic Surgery at the University
Hospital of Vienna (Austria) or in the Department of Thoracic
Surgery of V. Monaldi Hospital, Naples (Italy). One surgeon
(A.M.G. or W.K.) from our research group was always the
principal surgeon of the surgical team.
Neoplastic freshly frozen tissues also were available from
54 patients who had not undergone any adjuvant therapy. Sex
was unevenly distributed, with women accounting for 21.5%
of the population, and the mean patient age was 62 years.
Follow-up data were collected from the Central Institute of
Statistics of Austria, from hospital charts, and from periodic
interviews with patients and their families. The histologic
diagnoses and classifications of the tumors were based on the
World Health Organization criteria.12 The postoperative
pathologic TNM stage was determined according to the
guidelines of the American Joint Committee on Cancer.13
Polymerase chain reaction (PCR) and direct sequenc-
ing. Genomic DNA of normal tumor tissues was extracted
from 54 micro-dissected frozen specimens, and exons 1 and
2 of the p16 gene were amplified as previously described.14
PCR products then were purified (QIAquick PCR purifica-
tion kit, Germany) and sequenced by Dyedeoxy terminator
reaction chemistry for sequence analysis on the Applied
Biosystem model 377 DNA sequencing system (Foster City,
Calif).
Western blot analysis. One gram of each frozen lung can-
cer tissue sample was sectioned and quickly homogenized at
4°C in 250 mmol/L NaCl, 50 mmol/L tromethamine (Tris,
pH 7.4), 5 mmol/L EDTA, 0.1% Triton X-100, 1 mmol/L
phenylmethylsulfonyl fluoride, 50 mmol/L NaF, 0.5 mmol/L
Na3VO4, 10 mg/mL leupeptin, and 50 mg/mL aprotinin. The
homogenates were cleared by centrifugation for 15 minutes
at 13,000g at 4°C, and the total protein in the extracts was
determined. Next, 50 mg of protein was denatured by boiling
in 2X Laemmli sample buffer and separated by electrophore-
sis in a 15% sodium dodecyl sulfate–polyacrylamide gel, fol-
lowed by electrophoretic transfer of the proteins to a PVDF
membrane (Millipore, Bedford, Mass) in CAPS buffer (10
mmol/L CAPS, 20% methanol, pH 11). The membrane then
was blocked with 5% milk in TBS-T buffer (2 mmol/L
tromethamine [Tris], 13.7 mmol/L NaCl, 0.1% Tween-20, pH
7.6) and washed in TBS-T. Monoclonal mouse anti-p16 (F-
12) dilution 1 m g/mL (Santa Cruz Biotechnology, Inc, Santa
Cruz, Calif) was incubated with the membrane in 3% milk
and then washed in TBS-T. Secondary antibody, anti-mouse
coupled to horseradish peroxidase, was incubated with the
membrane and then washed in TBS-T. The presence of sec-
ondary antibody bound to the membrane was detected by using
the ECL system (DuPont NEN Company, Boston, Mass).
Immunohistochemistry. Sections from each specimen
were cut at 3 to 5 m m, mounted on glass, and dried overnight
at 37°C. All sections were deparaffinized in xylene, rehydrat-
ed through a graded alcohol series, and washed in phosphate-
buffered saline solution. This buffer was used for all subse-
quent washes and for dilution of the antibodies. Sections
were quenched sequentially in 0.5% hydrogen peroxide and
blocked with diluted 10% normal horse anti-mouse serum
(Vector Laboratories, Burlingame, Calif). A monoclonal anti-
body raised against p16 (F-12) (Santa Cruz Biotechnology)
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Table I. Frequency of distribution of clinical-pathologic
factors
Factor N %
Sex
Male 106 79
Female 29 21
Age (y)
≤60 50 37
>60 85 63
Histologic type
Adenocarcinoma 58 43
Squamous 54 40
Small cell carcinoma 22 16
Unknown 1 1
Tumor size
T1 34 25
T2 74 55
T3 9 7
T4 7 5
Tx 11 8
Nodal involvement
N0 48 36
N1 42 31
N2 24 18
N3 2 1
Nx 19 14
Metastasis
M0 110 81
M1 9 7
Mx 16 12
Tumor stage
T1 43 32
T2 40 22
T3a 28 21
T3b 7 5
T4 8 6
Unknown 19 14
Histologic grading
G1 5 4
G2 34 25
G3 52 38
Unknown 44 53
Postoperative radiotherapy
No 111 82
Yes 23 17
Unknown 1 1
Postoperative chemotherapy
No 112 83
Yes 23 17
was used (dilution 1:100). The incubation time was 60 min-
utes at room temperature. After being washed in phosphate-
buffered saline solution, the slides were incubated with dilut-
ed horse anti-mouse biotinylated antibody (Vector
Laboratories) for 30 minutes at room temperature.
All slides were processed by the ABC method (Vector
Laboratories) for 30 minutes at room temperature. Diamino-
benzidine was used as the final chromogen, and hematoxylin
was used as the nuclear counterstain. Negative controls for
each tissue section were prepared by leaving out the primary
antibody. Immunostaining of Saos-2 cells was used as the
positive control15 (data not shown).
All samples were processed under the same conditions.
Two pathologists (G.G. and F.B.) independently evaluated the
staining pattern of the protein. As previously described,15,16 a
tumor is considered p16 negative if there is no nuclear stain-
ing in any neoplastic cell regardless of cytoplasmatic staining
and if admixed non-neoplastic elements do show nuclear
immunoreactivity. If the latter are negative as well, the stain
is considered uninterpretable. A cutoff of 1% of positive cells
also was adopted. Specimens with less than 1% of positive
cells also were included in the first group (score 0, unde-
tectable expression). All specimens evaluated as positive
were scored according to the sequential arbitrary cutoffs:
score 1, from 1% to 30% of positive cells (low expression
level); score 2, from 30% to 60% of positive cells (medium
expression level); and score 3, more than 60% of positive
cells (high expression level). Analysis of the data with these
arbitrary cutoffs was highly statistically significant and,
therefore, functionally operative. At least 20 high-power
fields were chosen randomly and 2000 cells were counted.
Statistical analysis. We performed a statistical analysis to
investigate the relationship between the clinical-pathologic
parameters (age, sex, histotype, TNM status, tumor stage, and
postoperative radiation or chemotherapy), p16 expression,
and the patient survival times. Univariate analysis of survival
times was carried out by means of Kaplan-Meier analysis
stratified by the individual covariates. In most patients the log
rank test was used to test homogeneity of survival over stra-
ta. In a few patients, the Wilcoxon test was used because the
alternative hypothesis in this last test is that there is a decreas-
ing proportional difference across strata. This test is appro-
priate when one suspects an effect that may diminish over
time. In contrast, the alternative hypothesis in the log rank
test is that there is a proportional difference in survival across
strata that remains constant. Multivariate Cox proportional
hazards models were fit using all variables that were <.15 at
the univariate level.
Linear-by-linear and Kruskal-Wallis association tests were
used to assess possible associations among clinical-patholog-
ic parameters, Western blot p16 expression levels, and
immunohistochemical data. The analysis was performed with
the use of Stata 5.0 (Stata Corp 1997, Stata Statistical
Software, release 5.0, Stata Corporation, College Station, Tex).
Results
Table I summarizes the clinical-pathologic features
of the patients included in the study. PCR amplification
and direct sequencing performed on the 54 freshly
frozen specimens did not show any alteration in p16
exons 1 and 2. The immunohistochemical expression
of p16 was detected mostly in the nuclei of both normal
and neoplastic cells (Fig 1). Thirty-six specimens were
considered uninterpretable according to the criteria
described in the “Material and methods” section.
The level of agreement between the observers was
91.1% (123 specimens). In the remaining 12 specimens
the score was obtained from the opinion of a third
observer (A.G.). In 10 specimens (10.1%), p16 expres-
sion was undetectable. Score 1 was attributed to 27
specimens (27.3%), score 2 was attributed to 32 speci-
mens (32.3%), and score 3 was attributed to 30 speci-
mens (30.3%). Western blot analysis performed on 54
specimens showed different expression levels of p16
ranging from undetectable levels (6 specimens, 11.1%)
to high expression levels (15 specimens, 27.7%) (Fig
2). These results correlated highly with the immuno-
histochemical findings (P = .0002). No correlation was
found between p16 immunohistochemical expression
and any clinical-pathologic factor (ie, tumor stage and
histotype) (Table II). Tables III and IV show the sum-
mary of univariate and multivariate analyses of survival
times. At the univariate level, the percentage of p16
positive cells, the tumor stage, and the histologic type
correlate with patient overall survival. However, in a
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Fig 2. Western blot analysis of a representative panel of lung
cancer specimens showing different p16 expression levels.
Western blot was normalized with monoclonal antibody
anti–heat shock protein (HSP 72/73) purchased from
Oncogene Science Diagnostics, Inc (Cambridge, Mass).
Table II. Relationship between p16 expression and
tumor stage
Stage
p16 1 2 3a 3b 4
0 2 1 3 1 1
1 8 4 12 1 1
2 9 8 5 2 1
3 13 3 2 2 3
multivariate analysis, models controlled for sex, stage,
nodal status, and treatment (radiation and chemothera-
py) and stratified by histotype show p16 expression to
be an independent prognostic factor with its higher
expression correlating with longer patient survival time
(Fig 3).
Discussion
Lung cancer is a disease characterized by a complex
array of biomolecular alterations that drive uncon-
trolled growth and metastatic spread. Identification of
these alterations could provide a variety of molecular
markers, and tests could redefine the criteria for cancer
diagnosis and provide for new approaches to treatment.
Development of new diagnostic assays then could
expand the ability of clinicians to accurately stage
tumor development and to better predict clinical out-
comes by matching patients to different therapeutic
treatments.
These changes that lead to loss of cell cycle inhibi-
tion by negative regulators, such as p16, which releases
lung cancer cells from the constraints of cell division,
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Fig 3. Kaplan-Meier survival percentage curves for patients
with lung cancer constructed according to different p16 status.
Table III. Univariate Kaplan-Meier analysis 
Median 
survival 
Factor N (mo) 95% CI P value
Sex
1 103 27 (23, 30)
2 30 32 (25, 45) .11
Stage
1 44 30 (22, 46)
2 29 23 (19, 30)
3A 26 27 (11, 33)
3B 7 26 (9, 37)
4 8 26 (19, 46) <.001
Radiotherapy*
0 108 30 (25, 33)
1 25 21 (11, 29) .06 LR
p16 status
0 10 10 (6, 14)
1 28 16 (11, 19)
2 32 30 (25, 33)
3 30 46 (40, 54) <.001
Nodal status
0 47 28 (23, 36)
1 39 27 (20, 30)
2 25 21 (11, 32)
3 2 21 (9, 33) .10
Metastasis
0 107 27 (23, 32)
1 10 25 (19, 46) .68
Tumor size
1 34 25 (21, 40)
2 72 27 (21, 30)
3 9 27 (20, XX)
4 7 26 (12, 37) .61
Chemotherapy*
0 109 28 (25, 32)
1 23 25 (12, 30) .06
Histotype
Adenocarcinoma 57 30 (27, 33)
Squamous 54 26 (19, 32)
SCLC 21 16 (10, 40) .002 WI†
CI, Confidence interval; SCLC, small cell lung cancer.
*Patients who underwent postoperative radiotherapy or chemotherapy were
indicated with score = 1; others were indicated with score = 0.
†WI P values were obtained via the Wilcoxon test. All other P values were
based on the log rank (LR) test.
Table IV. Multivariate Cox proportional hazards
Variable Risk ratio Lower Upper P value
Sex 0.739 0.291 1.879 .53
Stage
2 2.452 0.415 14.485 .32
3a/3b 0.756 0.184 3.105 .70
4 5.276 0.717 38.799 .10
N
1 0.934 0.174 5.006 .94
2 2.918 0.785 10.847 .11
p16
1 0.234 0.077 0.715 .01
2 0.049 0.014 0.168 <.001
3 0.025 0.007 0.093 <.001
are regarded now as target events for new biomolecular
assays. We found altered p16 immunohistochemical
expression to be a rather frequent event in lung cancer
and to be independent of the histologic type of cancer
or other clinical-pathologic features. Expression of p16
was undetectable in 10.1% of the specimens, expressed
in less than 30% of neoplastic cells in 27.3% of the
specimens, expressed in 30% to 60% of cells in 32.3%
of the specimens, and detectable in more than 60% of
cells in only 30.3% of the specimens. Our Western blot
analyses highly correlated with these findings (P =
.0002). These data are in agreement with the findings of
Geradts and Wilson,17 who reported a high frequency
of aberrant p16 expression in 104 human breast cancers
but did not correlate this finding with histopathologic
parameters. Washimi and associates,18 however,
described p16 structural alterations that preferentially
affected non–small cell lung cancers in vivo, and
Kratzke and coworkers16 recently reported a high fre-
quency of p16 aberrant expression in non–small cell
lung cancer to be inversely related to the pathologic
stage of the disease. In addition, we also conclude that
p16 immunohistochemical expression is a favorable
independent prognostic factor in lung cancer.
Reduction or loss of p16 expression correlates with a
worse patient outcome.
These results, obtained on a large number of patients
including those with small cell carcinomas, confirm the
suggestion of Kratzke and associates16 that absent or
reduced p16 expression is a negative prognostic indicator.
In this study, PCR amplification and direct sequenc-
ing of p16 exons 1 and 2 revealed no mutations, indi-
cating that p16-altered expression in lung cancer is not
linked necessarily to mutational events of these gene.
Previous studies have reported contrasting results both
in lung cancer and in tumors from other anatomic sites.
These studies described p16 aberrant expression to be
either a frequent consequence of DNA alterations5,18,19
or a post-transcriptional event.8,20-23 DNA hypermethy-
lation has been proposed recently as an alternative
mechanism for p16 gene functional inactivation.24,25
In conclusion, our study demonstrated that p16-
altered expression is a frequent event in lung cancer.
These data attribute an important role to this protein
during both tumorigenesis and tumor progression in a
significant proportion of patients with lung cancer,
even though the incidence and the relevance of p16
mutations in this neoplasm remain debatable and its
analysis seems inconclusive.
Our results suggest an important role for the immun-
odetection of this protein on formalin-fixed and paraf-
fin-embedded specimens. If confirmed in larger groups
of patients, this simple assay could be of value in the
evaluation of the frequently unpredictable behavior of
lung cancer.
We thank Dr J. J. Gartland, Thomas Jefferson University
medical editor, for editing the manuscript.
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